3.
Fleischner学会关于CT检查发现的肺内伴实性结节的随访建议
Recommendations for the management of subsolid pulmonry nodules detected at CT: A statement from the Fleischner scocity
| Nodule type | Management recommendations | Additional remarks |
| GGN, ground glass nodule; These guidelines assume meticulous evaluation, optimally with contiguous thin sections (1 mm) reconstructed with narrow and/or mediastinal windows to evaluate the solid component and wide and/or lung windows to evaluate the nonsolid component of nodules, if indicated. The use of a consistent low-dose technique is recommended. With serial scans, always compare with the original baseline study to detect subtle indolent growth. | ||
| Solitary pure GGNs | ||
| ≤5 mm | No CT follow-up required | Obtain contiguous 1 mm thick sections to confirm that nodule is truly a pure GGN |
| > 5 mm | Initial follow-up CT at 3 months to confirm persistence then annual surveillance CT for a minimum of 3 years | FDG PET is of limited value, potentially misleading, and therefore not recommended |
| Solitary part-solid nodules | Initial follow-up CT at 3 months to confirm persistence. If persistent and solid component < 5 mm,then yearly surveillance CT for a minimum of 3 years. If persistent and solid component ≥5 mm,then biopsy or surgical resection | Consider PET/CT for part-solid nodules > 10 mm |
| Multiple subsolid nodules | ||
| Pure GGNs ≤5 mm | Obtain follow-up CT at 2 and 4 years | Consider alternate causes for multiple GGNs ≤5 mm |
| Pure GGNs > 5 mm without a dominant lesion (s) | Initial follow-up CT at 3 months to confirm persistence and then annual surveillance CT for a minimum of 3 years | FDG PET is of limited value, potentially misleading, and therefore not recommended |
| Dominant nodule (s) with part-solid or solid component | Initial follow-up CT at 3 months to confirm persistence. If persistent biopsy or surgical resection is recommended, especially for lesions with > 5 mm solid component | Consider lung-sparing surgery for patients with dominant leision (s) suspicious for lung cancer |